Experimental eye research · 2025
Plumbagin protects against cataract formation in STZ-induced diabetic rats: Establishing insights into the molecular mechanism.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Yadav Apurva, Choudhary Rajesh, Ram Anshul, Nirmalkar Umashankar, Shree Jaya, Paul Swarnali Das, Verma Vinay Sagar
Аннотация
BACKGROUND: Our previous study demonstrated that plumbagin has the potential to reduce the lens aldose reductase and mitigate the cataract formation in the glucose-induced ex vivo model. Therefore, we explored the molecular insights into the anticataract action of plumbagin using the STZ-induced in vivo diabetic rat model.
METHODS: Albino rats (Wistar rats, 150-180 g body weight, 15-18 weeks old, of either sex) were used in the study for assessment of the anticataract action of plumbagin against the STZ-induced diabetic cataract rat model. STZ was intraperitoneally injected at a dose of 60 mg/kg to induce diabetes in rats. Following 3 days of STZ treatment, hyperglycemic rats received either vehicle (DCC group), metformin (200 mg/kg/day, p. o., MetC group), or plumbagin at two dose levels: 15 mg/kg/day, p. o. (Plg-15 group) and 30 mg/kg/day, p. o. (Plg-30 group) in the respective groups (with six rats in each group) for ten consecutive weeks.
RESULTS: An in vitro study showed positive antiglycation activity of plumbagin. The research revealed that plumbagin, especially at a dose of 30 mg/kg, had potent antidiabetic and anticataract activity against STZ exposure. Plumbagin treatments significantly (P < 0.05 vs. DCC group) reduced blood glucose levels and increased body weight. Additionally, plumbagin significantly (P < 0.05 vs. DCC group) mitigated the progression of cataract maturation and restored all pathogenic markers, including polyol content, antioxidants, nitrite content, lipid peroxidation, ATPase pump activities, ion levels, and protein content in the eye lenses.
CONCLUSION: The study strongly supports plumbagin as a promising phytotherapeutic agent for the management of diabetic cataract, primarily through its potent polyol inhibition, antiglycation, antioxidant, and ion-regulating properties, which collectively contribute to preserving the lens transparency and function in diabetic conditions.
METHODS: Albino rats (Wistar rats, 150-180 g body weight, 15-18 weeks old, of either sex) were used in the study for assessment of the anticataract action of plumbagin against the STZ-induced diabetic cataract rat model. STZ was intraperitoneally injected at a dose of 60 mg/kg to induce diabetes in rats. Following 3 days of STZ treatment, hyperglycemic rats received either vehicle (DCC group), metformin (200 mg/kg/day, p. o., MetC group), or plumbagin at two dose levels: 15 mg/kg/day, p. o. (Plg-15 group) and 30 mg/kg/day, p. o. (Plg-30 group) in the respective groups (with six rats in each group) for ten consecutive weeks.
RESULTS: An in vitro study showed positive antiglycation activity of plumbagin. The research revealed that plumbagin, especially at a dose of 30 mg/kg, had potent antidiabetic and anticataract activity against STZ exposure. Plumbagin treatments significantly (P < 0.05 vs. DCC group) reduced blood glucose levels and increased body weight. Additionally, plumbagin significantly (P < 0.05 vs. DCC group) mitigated the progression of cataract maturation and restored all pathogenic markers, including polyol content, antioxidants, nitrite content, lipid peroxidation, ATPase pump activities, ion levels, and protein content in the eye lenses.
CONCLUSION: The study strongly supports plumbagin as a promising phytotherapeutic agent for the management of diabetic cataract, primarily through its potent polyol inhibition, antiglycation, antioxidant, and ion-regulating properties, which collectively contribute to preserving the lens transparency and function in diabetic conditions.